Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:NARI NYSE:NVRO NASDAQ:SWAV NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$80.89+0.2%$102.87$73.92▼$218.52$2.39B1.15963,835 shs708,369 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.49 million shsN/ANVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsSWAVShockwave Medical$334.75$332.85$157.00▼$334.90$12.57B0.88968,088 shsN/ATNDMTandem Diabetes Care$12.43+2.8%$13.41$9.98▼$47.60$816.91M1.451.72 million shs1.85 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-0.01%-0.53%-7.73%-37.75%-61.10%NARIInari Medical0.00%0.00%0.00%0.00%+72.91%NVRONevro0.00%0.00%0.00%0.00%+1.49%SWAVShockwave Medical0.00%0.00%0.00%0.00%0.00%TNDMTandem Diabetes Care+2.81%-1.04%+14.88%-39.10%-70.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$80.89+0.2%$102.87$73.92▼$218.52$2.39B1.15963,835 shs708,369 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.49 million shsN/ANVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsSWAVShockwave Medical$334.75$332.85$157.00▼$334.90$12.57B0.88968,088 shsN/ATNDMTandem Diabetes Care$12.43+2.8%$13.41$9.98▼$47.60$816.91M1.451.72 million shs1.85 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-0.01%-0.53%-7.73%-37.75%-61.10%NARIInari Medical0.00%0.00%0.00%0.00%+72.91%NVRONevro0.00%0.00%0.00%0.00%+1.49%SWAVShockwave Medical0.00%0.00%0.00%0.00%0.00%TNDMTandem Diabetes Care+2.81%-1.04%+14.88%-39.10%-70.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.57Moderate Buy$164.50103.36% UpsideNARIInari Medical 2.09Hold$72.57-9.25% DownsideNVRONevro 2.00Hold$5.36-8.29% DownsideSWAVShockwave Medical 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.31Hold$22.4480.51% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, SWAV, TNDM, NARI, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025TNDMTandem Diabetes CareOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.00 ➝ $22.009/2/2025INSPInspire Medical SystemsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$150.008/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/15/2025INSPInspire Medical SystemsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$116.00 ➝ $97.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $25.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M2.98$1.71 per share47.26$23.01 per share3.52NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72SWAVShockwave Medical$787.97M15.95$4.31 per share77.61$20.02 per share16.72TNDMTandem Diabetes Care$940.20M0.89N/AN/A$4.01 per share3.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$1.7346.7625.122.526.17%10.38%8.93%11/3/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%N/ASWAVShockwave Medical$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/ATNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest NVRO, SWAV, TNDM, NARI, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million8/4/2025Q2 2025INSPInspire Medical Systems$0.22$0.45+$0.23-$0.12$214.50 million$217.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ASWAVShockwave MedicalN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.144.84NARIInari MedicalN/A1.771.40NVRONevro0.675.023.76SWAVShockwave Medical0.9713.8112.61TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%NARIInari Medical90.98%NVRONevro95.52%SWAVShockwave Medical95.35%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.30%NARIInari Medical10.60%NVRONevro3.20%SWAVShockwave Medical3.40%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.57 million28.89 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableSWAVShockwave Medical1,46837.54 million36.27 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableNVRO, SWAV, TNDM, NARI, and INSP HeadlinesRecent News About These CompaniesTandem Diabetes announces publication of 2IQP study in Diabetes Care3 hours ago | msn.comTandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels3 hours ago | theglobeandmail.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 16 at 6:40 PM | globenewswire.comAcadian Asset Management LLC Takes Position in Tandem Diabetes Care, Inc. $TNDMSeptember 16 at 3:35 AM | marketbeat.comJim Cramer Calls Tandem Diabetes “Speculative Stock for Younger People”September 13, 2025 | insidermonkey.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM),September 12, 2025 | bakersfield.comBTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 12, 2025 | globenewswire.comAnalysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Target Price at $22.47September 11, 2025 | americanbankingnews.comTandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold RatingSeptember 10, 2025 | tipranks.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMSeptember 10, 2025 | tmcnet.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDMSeptember 10, 2025 | businesswire.comTandem Diabetes Care, Inc. (TNDM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Now Covered by Analysts at OppenheimerSeptember 10, 2025 | marketbeat.comFred Alger Management LLC Sells 489,117 Shares of Tandem Diabetes Care, Inc. $TNDMSeptember 10, 2025 | marketbeat.comOppenheimer Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)September 10, 2025 | americanbankingnews.comBeyond The Numbers: 12 Analysts Discuss Tandem Diabetes Care StockSeptember 9, 2025 | benzinga.comShort Interest in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Decreases By 34.1%September 9, 2025 | marketbeat.comSessa Capital IM L.P. Acquires Shares of 4,466,307 Tandem Diabetes Care, Inc. $TNDMSeptember 9, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesSeptember 9, 2025 | marketbeat.comPark West Asset Management LLC Has $21.52 Million Stake in Tandem Diabetes Care, Inc. $TNDMSeptember 8, 2025 | marketbeat.comTandem Diabetes Care, Inc. $TNDM Shares Sold by Jacobs Levy Equity Management Inc.September 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Super Micro Computer Stock Hasn't Priced in Growth YetBy Gabriel Osorio-Mazilli | August 25, 20253 Undervalued Stocks Analysts Are Loving Right Now—Should You?By Gabriel Osorio-Mazilli | August 27, 2025Lululemon’s Sell-Off Looks Overdone: A Contrarian CaseBy Sam Quirke | September 16, 2025NVRO, SWAV, TNDM, NARI, and INSP Company DescriptionsInspire Medical Systems NYSE:INSP$80.89 +0.15 (+0.19%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$80.83 -0.06 (-0.07%) As of 09/16/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Inari Medical NASDAQ:NARIInari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Nevro NYSE:NVRONevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Shockwave Medical NASDAQ:SWAVShockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.Tandem Diabetes Care NASDAQ:TNDM$12.43 +0.34 (+2.81%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$12.38 -0.05 (-0.39%) As of 09/16/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
